PSCA-directed nanosized bio-immune conjugates (NANO:BICs) enable selective uptake of TLR9 agonists in bladder cancer cells [0.03%]
PSCA定向的纳米生物免疫共轭物(NANO:BICs)能够在膀胱癌细胞中选择性摄取TLR9激动剂
Max Iltzsche,Nancy Wetterling,Lissy Jilek et al.
Max Iltzsche et al.
Introduction: Bladder cancer (BCa), particularly non-muscle invasive bladder cancer (NMIBC), remains a significant healthcare challenge due to high recurrence rates and limited non-surgical treatment options. ...
Preoperative nutritional status and sarcopenia are associated with disease-free survival in patients with resected pancreatic neuroendocrine tumors [0.03%]
术前营养状况和少肌症与手术胰神经内分泌肿瘤患者无病生存率相关性研究
Jincheng Li,Mingyu Lai
Jincheng Li
Background: Pancreatic neuroendocrine tumors (pNETs) show heterogeneous clinical behavior, and better predictors of postoperative recurrence are needed. M...
Ensemble CNN for colon cancer detection using histopathological image [0.03%]
基于组织病理图像的大肠癌检测的集成CNN方法
Akshay Kulkarni,Amit Upadhyay,Monika Mangla et al.
Akshay Kulkarni et al.
Colon cancer remains one of the leading causes of cancer-related mortality worldwide, with delayed detection significantly impacting survival rates. The time-consuming nature of traditional histopathological analysis contributes to these di...
Case Report: Synchronous colorectal adenocarcinomas with discordant mismatch repair status: a case of lynch-like syndrome and serrated pathway association [0.03%]
案例报告：错配修复状况不同的同步性结直肠腺癌：类似林奇综合征和微卫星型途径相关性病例
Daming Chen,Jiansheng Zhang,Jinchao Bi et al.
Daming Chen et al.
Objective: Synchronous colorectal cancers (SCRCs) with discordant mismatch repair (MMR) status present unique clinical and therapeutic challenges. This case report describes a rare instance of synchronous ascending colon ...
Bridging practice and precision: a quantitative HER2 protein assay ready for clinical use in guiding trastuzumab deruxtecan therapy [0.03%]
从实践中求精炼——首个可用于指导T-DXd治疗的HER2蛋白定量检测问世
Junmei Hao,Xiaochun Fei,Fangfang Zou et al.
Junmei Hao et al.
Purpose: Current daily usage of Trastuzumab Deruxtecan (T-DXd) is guided by immunohistochemistry (IHC)-based HER2 assessment, with known inconsistency and inaccuracy to differentiating IHC 0 from 1 +. In this study, a qua...
Pituitary T-lymphoblastic lymphoma combined with pituitary adenoma: a rare case report [0.03%]
垂体T淋巴母细胞淋巴瘤合并垂体腺瘤一例报告
Xiaoyu Chen,Long Cheng,Zhiping Li et al.
Xiaoyu Chen et al.
Background: T-cell lymphoblastic lymphoma (T-LBL) is a highly aggressive malignancy that originates from immature precursor T lymphocytes and is characterized by rapid progression. The typical clinical manifestations of T...
Research progress of antibody-drug conjugates in the treatment of endometrial cancer [0.03%]
抗体偶联药物治疗子宫内膜癌的研究进展
Yuying Jiang,Qin Yao
Yuying Jiang
As a significant threat to women's health worldwide, the incidence of endometrial cancer is rising annually, and current treatment options have limited effectiveness for advanced-stage patients. The use of antibody-drug conjugates (ADCs) in...
Efficacy and safety of subcutaneous versus intravenous administration of PD-1/PD-L1 inhibitors in the treatment of solid tumors: a systematic review and meta-analysis [0.03%]
程序性死亡受体1及其配体1抑制剂皮下给药与静脉给药治疗实体瘤疗效和安全性的系统评价和 Meta 分析
Peiye Wu,Zhanpeng Liang,Zhaoyang Wu et al.
Peiye Wu et al.
Objective: The aim was to evaluate the differences in pharmacokinetics, clinical efficacy, and safety between subcutaneous (s.c.) and intravenous (i.v.) administration of PD-1/PD-L1 inhibitors in the treatment of solid tu...
ADAMTS2 drives prostate cancer progression by activating FAK/PI3K/AKT signaling and suppressing ferroptosis via COL1A1 [0.03%]
ADAMTS2通过激活FAK/PI3K/AKT信号传导并抑制COL1A1诱导的铁死亡来促进前列腺癌进展
Jinzhuo Ning,Jinrun Wang,Lizhe Xu et al.
Jinzhuo Ning et al.
Background: ADAMTS2, a secreted metalloproteinase essential for collagen maturation, exhibits context-dependent roles in cancer but remains uncharacterized in prostate cancer (PCa). Its potential involvement in PCa progre...
Retraction: Corrigendum: Chamaejasmin B decreases malignant characteristics of mouse melanoma B16F0 and B16F10 cells [0.03%]
撤稿：校正：喜马素B减少鼠黑色素瘤b16f0和b16f10细胞的恶性特征
Frontiers Editorial Office
Frontiers Editorial Office
[This retracts the article DOI: 10.3389/fonc.2024.1472829.]. Copyright © 2026 Frontiers Editorial Office.